首页> 外文期刊>Journal of chemical information and modeling >Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation
【24h】

Discovery of Ubiquitin-Specific Protease 7 (USP7) Inhibitors with Novel Scaffold Structures by Virtual Screening, Molecular Dynamics Simulation, and Biological Evaluation

机译:通过虚拟筛选,分子动力学模拟和生物学评估,发现泛素特异性蛋白酶7(USP7)抑制剂具有新型支架结构

获取原文
获取原文并翻译 | 示例
       

摘要

USP7 has been regarded as a potential therapeutic target for cancer. In this study, virtual screening, molecular dynamics (MD) simulation, and biological evaluation have been applied for the discovery of novel USP7 inhibitors targeting the catalytic active site. Among the obtained compounds, compound 12 with a novel scaffold structure exhibited certain USP7 inhibitory activity (Ub-AMC assay IC50 = 18.40 +/- 1.75 mu M, Ub-Rho assay IC50 = 7.75 mu M). The binding affinity between USP7(CD) (USP7 catalytic domain) and this hit compound was confirmed with a K-D value of 4.46 +/- 0.86 mu M. Preliminary in vitro studies disclosed its antiproliferative activity on human prostate cancer cell line LNCaP with an IC50 value of 15.43 +/- 3.49 mu M. MD simulation revealed the detailed differences of protein-ligand interactions between USP7(CD) and the ligands, including the reference compound ALM4 and compound 12, providing some important information for improving the bioactivity of 12. This hit compound will serve as a promising starting point for facilitating the further discovery of novel USP7 inhibitors.
机译:USP7被认为是癌症的潜在治疗目标。在本研究中,已经应用了虚拟筛选,分子动力学(MD)模拟和生物学评估,用于发现靶向催化活性位点的新型USP7抑制剂。在所得化合物中,具有新型支架结构的化合物12表现出某些UB-AMC测定IC50 = 18.40 +/-1.75μm,UB-RHO测定IC50 =7.75μm)。通过KD值为4.46 +/-0.86μm,确认USP7(CD)(USP7)(USP7催化结构域)和该击中化合物之间的结合亲和力。初步体外研究公开了其与IC50的人前列腺癌细胞系LNCAP上的抗增殖活性值为15.43 +/- 3.49 mu M. MD模拟显示USP7(CD)和配体之间的蛋白质 - 配体相互作用的详细差异,包括参考化合物ALM4和化合物12,提供了改善12的生物活性的一些重要信息。这种受欢迎的化合物将作为促进新型USP7抑制剂进一步发现的有希望的起点。

著录项

  • 来源
  • 作者单位

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    Guangxi Normal Univ Sch Chem &

    Pharm State Key Lab Chem &

    Mol Engn Med Resources Guilin 541004 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

    China Pharmaceut Univ Jiangsu Key Lab Drug Discovery Metab Dis Nanjing 210009 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;化学工业;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号